Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis

Although conceptual, these data suggest that neoadjuvant therapy offers substantial benefit in LE and QALE for resectable pancreatic cancer patients. These findings highlight the value of further prospective randomized trials comparing neoadjuvant therapy to conventional upfront surgical strategies.